



Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 11

## Complete if Known

Application Number	10/533,025
Filing Date	04/26/2005
First Named Inventor	Behr
Art Unit	1655
Examiner Name	Qiuwen Mi
Attorney Docket Number	41313-1004

## U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A	US- 2001/00513347	12-13-2001	Kundu, et al.	
	B	US- 2003/0077685	04-24-2003	Schmidt, et al.	
	C	US- 2003/0099631	05-29-2003	Koji, et al.	
	D	US- 2004/0234480	11-25-2004	Pauly, et al.	
	E	US- 2006/0228426	10-12-2006	Cyr	
	F	US- 4,855,131	08-08-1989	Iris	
	G	US- 4,857,325	08-15-1989	Albeck, et al.	
	H	US- 4,923,697	05-08-1990	Albeck, et al.	
	I	US- 5,073,545	12-17-1991	Arima, et al.	
	J	US- 5,141,741	08-25-1992	Ishida, et al.	
	K	US- 5,627,216	05-06-1997	Papadopoulos	
	L	US- 5,665,367	09-09-1997	Burger, et al.	
	M	US- 5,824,320	10-20-1998	Rouillard, et al.	
	N	US- 5,837,224	11-17-1998	Voorhees, et al.	
	O	US- 5,935,809	08-10-1999	Ryan, Jr., et al.	
	P	US- 6,079,415	06-27-2000	Berner, et al.	
	Q	US- 6,096,711	08-01-2000	Sherman, et al.	
	R	US- 6,130,254	10-10-2000	Fisher, et al.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†*
		Country Code <sup>3</sup> "Number" "Kind Code" (if known)				
	S	CA 1,298,558	04-07-1992	Rudov		
	T	CA 2,087,600	03-18-1997	D'Amigo		
	U	CA 2,092,821	11-19-2002	Okpanyi		
	V	CA 2,185,983	04-13-2004	Kwak et al.		
	W	CA 2,189,486	05-04-1998			

Examiner Signature	/Qiuwen Mi/	Date Considered	06/17/2008
--------------------	-------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2

of 11

**Complete if Known**

Application Number	10/533,025
Filing Date	04/26/2005
First Named Inventor	Behr
Art Unit	1655
Examiner Name	Qiuwen MI
Attorney Docket Number	41313-1004

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	X	us-6,177,122	01-23-2001	Fahey, et al.	
	Y	us-6,193,975	02-27-2001	Bonte, et al.	
	Z	us-6,271,001	08-07-2001	Clarke, et al.	
	AA	us-6,307,101	10-23-2001	Campbell, et al.	
	AB	us-6,342,208	01-29-2001	Hyldgaard, et al.	
	AC	us-6,365,630	04-02-2002	Fisher, et al.	
	AD	us-6,406,720	06-18-2002	Pauly, et al.	
	AE	us-6,432,456	08-13-2002	Mori	
	AF	us-6,676,975	01-13-2004	Whittle, et al.	
	AG	us-6,682,763	01-27-2004	Kuno, et al.	
	AH	us-6,762,280	07-13-2004	Schmidt, et al.	
	AI	us-6,764,693	07-20-2004	Smith	
	AJ	us-6,800,292	10-05-2004	Murad	
	AK	us-			
	AL	us-			
	AM	us-			
	AN	us-			
	AO	us-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> "Number" <sup>4</sup> "Kind Code" <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	<sup>1</sup>
	AP	CA 2,288,339	05-11-1998	Raskin		
	AQ	EP 1 275 372 A1	01-15-2003	Breton		
	AR	FR 2 812 544	02-08-2002	Liviero et al.		
	AS	JP 08104628	04-23-1996	Kumagai et al.		
	AT	JP 11079970	03-23-1999	Suzuki et al.		

Examiner Signature	/Qiuwen MI/	Date Considered	06/17/2008
--------------------	-------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/533,025
Filing Date	04/26/2005
First Named Inventor	Behr
Art Unit	1655
Examiner Name	Qiuwen MI
Attorney Docket Number	41313-1004

Sheet	4	of	11
-------	---	----	----

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1 <sup>st</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	AZ	JP 2003 201212	07-18-2003	Inomata et al.		
	BA	JP 2003 201229	07-18-2003	Inomata et al.		
	BB	WO 98/49267	11-05-1998	Raskin		
	BC	WO 00/07437	02-17-2000	Raskin		
	BD	WO 00/51562	09-08-2000	Inomata		

Examiner Signature	/Qiuwen Mi/	Date Considered	06/17/2008
-----------------------	-------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup>For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document. <sup>4</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>5</sup>Applicant is to place a check mark here if English language translation is attached.

Transmission of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

5

of

11

**Complete if Known**

Application Number	10/533.025
--------------------	------------

Filing Date	04/26/2005
-------------	------------

First Named Inventor	Behr
----------------------	------

Art Unit	1655
----------	------

Examiner Name	Qiuwen MI
---------------	-----------

Attorney Docket Number	41313-1004
------------------------	------------

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1 <sup>o</sup>
		Country Code <sup>2</sup> "Number" "Kind Code <sup>5</sup> (if known)"				
	BE	WO 00/62789	10-26-2000	Msika		
	BF	WO 02/11745	02-14-2002	Kim et al.		
	BG	WO 02/34231	05-02-2002	Breton et al.		
	BH	WO 02/34276	05-02-2002	Breton et al.		
	BI	WO 02/069992	09-12-2002	Cyr		

Examiner Signature	/Qiwen Mi/	Date Considered	06/17/2008
-----------------------	------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document for the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINE

American ExpressNet, Inc.  
www.BornToWork.com

/QM/

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet	6
-------	---

of 11

Application Number	10/533,025
Filing Date	04/26/2005
First Named Inventor	Behr
Art Unit	1655
Examiner Name	Qiuwen MI
Attorney Docket Number	41313-100

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> "Number" <sup>4</sup> "Kind Code" <sup>5</sup> (if known)	MM-DD-YYYY			
	BJ	RU 2141328	11-20-1999	Chenکو et al.		
	BK	WO 03/035092	05-01-2003	Kim		

Examiner Signature	/Qiuwen Mi/	Date Considered	06/17/2008
--------------------	-------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/533,025
Filing Date	04/26/2005
First Named Inventor	Behr
Art Unit	1655
Examiner Name	Qiuwen MI
Attorney Docket Number	41313-1004

Sheet 7

of

11

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BL	Y. Allanore et al., (2003), J. Rheumatol., 30(1):68-73	
	BM	A. Berton et al., (2000), Matrix Biol, 19(2):139-146	
	BN	S. Bosset et al., (2003), Br J Dermatol., 148(4):770-8	
	BO	P. Brenneisen et al., (2002), Ultraviolet-B irradiation and matrix metalloproteinases: from induction via signaling to initial events. Ann NY Acad. Sci., 973:31-43	
	BP	M. Demeule et al., (2000), Biochimica et Biophysica Acta. Matrix metalloproteinase inhibition by green tea catechins, pp. 51-60	
	BQ	B. Dubois et al., (1998), Regulation of Gelatinase B (MMP-9) in Leukocytes by Plant Lectins, FEBS Lett., 427:275-278	
	BR	SE Fligiel et al., (2003), J. Invest Dermatol., 120(5):842-8	
	BS	D.C. Gervasi et al., (1996), Carbohydrate-Mediated Regulation of Matrix Metalloproteinase-2 Activation in Normal Human Fibroblasts and Fibrosarcoma Cells, Biochem. Biophys. Res. Comm., 228:530-538	
	BT	Y. Hojima et al., (Mar 1983), Survey of plant inhibitors of polymorphonuclear leukocyte elastase, pancreatic elastase, cathepsin G, Hageman factor fragments, and other serine proteinases, Biochem Pharmacol, 32(6) 985-990	
	BU	K.A. Homer et al., (1992), Inhibition of Peptidase and Glycosidase Activities of Porphyromonas-Gingivalis Bacteroides-Intermedius and Treponema-Denticola by Plant Extracts, Journal of Clinical Periodontology, 19:305-310	

Examiner Signature	/Qiuwen MI/	Date Considered	06/17/2008
--------------------	-------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/533,025
Filing Date	04/26/2005
First Named Inventor	Behr
Art Unit	1655
Examiner Name	Qiuwen Mi
Attorney Docket Number	41313-1004

Sheet 8

of 11

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	BV	N. Isnard et al., (2002), Biomed Pharmacother., July, 56(5):258-264	
	BW	S. Johansson et al., (2002), J. Nat Prod., 65:32-41	
	BX	M. Jonadet et al., (Jan-Mar 1986), [Flavonoids extracted from Ribes nigrum L. and Alchemilla vulgaris L.: 1. In vitro inhibitory activities on elastase, trypsin and chymotrypsin. 2. Angioprotective activities compared in vivo]. J. Pharmacol, 17(1):21-27.	
	BY	CM Keilty et al., (1994), FEBS Lett, 351:85-89	
	BZ	CM Keilty et al., (2002), J Cell Sci., 115:2817-2828	
	CA	Koch et al., (1991), Agents Actions, 34:350-7	
	CB	Krupa and Mort (2000), Anal Biochem., 283(1):99-103	
	CC	J. Labat-Robert et al., (2000), Age dependent increase of elastase type protease activity in mouse skin. Effect of UV-irradiation, J. Photochem Photobiol B, 57(2-3):113-8	
	CD	K.K. Lee et al., (1999), Inhibitory Effects of 150 Plant Extracts on Elastase Activity and Their Anti-inflammatory Effects, International Journal of Cosmetic Science, Vol. 21, No. 2, pp. 71-82	
	CE	F. Lopez et al., (1994), Accumulation of a 22-kDa protein and its mRNA in the leaves of Raphanus sativus in response to salt stress or water deficit, Physiologia Plantarum, 91:605-614	

Examiner Signature	/Qiuwen Mi/	Date Considered	06/17/2008
--------------------	-------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

**Complete if Known**

Application Number 10/533,025  
Filing Date 04/26/2005  
First Named Inventor Behr  
Art Unit 1655  
Examiner Name Qiuwen Mi  
Attorney Docket Number 41313-1004

Sheet 9

of

11

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CF	WD McMillan et al., (1997), Circulation, 96:2228-2232	
	CG	MF Melzig et al., (Sept 1999), Inhibition of granulocyte elastase activity by caffeic acid derivatives, Pharmazie, 54(9) 712	
	CH	Nagase et al., (1998) Inhibitory Effect of Delphinidin from solanum Melongena on Human Fibrosarcoma HT-1080 Invasiveness in vitro, Planta Med., 64:216-219.	
	CI	Y. Nishimori et al., (2001), Degenerative alterations of dermal collagen fiber binds in photodamaged human skin and UV-irradiated hairless mouse skin: possible effect on decreasing skin mechanical properties .... J. Invest Dermatol., 117(6): 1458-63	
	CJ	Obayashi et al., (1998), Nippon Keshonin Gijutsusha Kaishi, 32:272-279	
	CK	Paemen et al., (1996) Biochem. Pharm. 52:105-111	
	CL	D.H. Paper, (1998), Natural Products as Angiogenesis Inhibitors, Planta Medica, Vol. 64, No. 8, pp. 686-695	
	CM	T. Reinheckel et al., (2001), Biol Chem, 382(5):735-741	
	CN	R. Roguet, (2002), Skin Pharmacol Appl Skin Physiol., 15 Suppl 1:1-3	
	CO	K. Sakuraoka et al., (1996), J Dermatol Sci, 12(3):232-237	

Examiner Signature	/Qiuwen Mi/	Date Considered	06/17/2008
--------------------	-------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.67 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH

American LegalNet, Inc.  
www.AmericanLegalNet.com

/QM/



Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/533,025
Filing Date	04/26/2005
First Named Inventor	Behr
Art Unit	1655
Examiner Name	Qiuwen MI
Attorney Docket Number	41313-1004

Sheet 10

of

11

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CP	B. Starcher et al., (1995), Ciba Found Symp, 192:338-46	
	CQ	M. Szendroi et al., (1984), J. Invest Dermatol, 83:224-229	
	CR	K. Tsukahara et al., (2001), Biol Pharm Bull, 24(9):998-1003	
	CS	RE Watson et al., (1999), J. Invest Dermatol., 112(5):782-7	
	CT	U. Wormser et al., (1997), Arch Dermatol Res., 289(12):686-691	
	CU	QL Ying et al., (July 1991), Inhibition of human leucocyte elastase by ursolic acid. Evidence for a binding site for pentacyclic triterpenes, Biochem J., 15:277 (pt 2) 521-526	
	CV	International Search Report from WO 2006/053415	
	CW	International Search Report from WO 2004/019961	
	CX	Office Action dated 10/06/2006 for U.S. Application No. 10/469,402	
	CY	Office Action dated 05/30/2007 for U.S. Application No. 10/469,402	

Examiner Signature	/Qiuwen MI/	Date Considered	06/17/2008
--------------------	-------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /QM/

Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/533,025
Filing Date	04/26/2005
First Named Inventor	Behr
Art Unit	1655
Examiner Name	Qiuwen MI
Attorney Docket Number	41313-1004

Sheet 11

of 11

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CZ	Office Action dated 02/27/2007 for U.S. Application No. 10/526,387	
	DA	Office Action dated 06/28/2007 for U.S. Application No. 10/526,387	
	DB	Office Action dated 10/21/2007 <sup>12</sup> for U.S. Application No. 10/526,387	

Examiner Signature	/Qiuwen Mi/	Date Considered	06/17/2008
--------------------	-------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /QM/